Kansel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kansel

Property Description
Active Ingredient Clotrimazole (INN)
Pharmacological Class Antifungal Agent (Imidazole Antimycotic)
Form Cream, Solution, Vaginal Tablet (Pessary)
Origin Synthetic chemical compound
General Purpose To arrest and resolve fungal proliferation

What Type of Medicine is Kansel?

Kansel is a medicinal product defined by its active pharmaceutical ingredient, Clotrimazole, a member of the Antifungal Agent class of medicines. It is specifically categorized as an Imidazole Antimycotic, a type of synthetic azole compound developed to counter pathogenic fungi. The chemical compound Clotrimazole is used for its broad-spectrum efficacy against many strains of yeast and dermatophytes. This classification establishes the drug's core utility: the localized management and resolution of mycological issues, which is its common use scenario.

Composition, Forms, and General Purpose

The composition of Kansel centers on the single active ingredient, Clotrimazole, combined with a suitable base material necessary for its intended delivery. The medicine is supplied in multiple common pharmaceutical preparations, primarily including a cream or solution for topical administration to the skin, and a vaginal tablet (pessary) for intravaginal use. This variety is intended to facilitate effectiveness, as the limited systemic absorption through the skin or mucosa allows for local concentration at the site of the fungal growth, minimizing wider systemic impact. The general purpose of administering Clotrimazole is to arrest fungal proliferation, which it achieves by disrupting a process in the fungal cell structure. The drug’s mechanism involves inhibiting the synthesis of ergosterol, a sterol crucial for maintaining the integrity and function of the fungal cell membrane, leading to compromised cellular viability and the suppression of fungal growth.

Regulatory References

  1. World Health Organization's List of Essential Medicines

What side effects are possible with Kansel?

The active ingredient in Kansel, Clotrimazole, has a safety profile defined by regulatory agencies based on frequency and the body system affected. Since the medicine is minimally absorbed systemically in its topical and vaginal forms, officially documented adverse reactions are primarily localized to the application site.

Officially Documented Local Reactions

Adverse effects involving the skin, subcutaneous tissue, or mucous membranes are the most common safety pattern listed in regulatory materials, often classified as common. These typically include localized experiences such as a burning sensation, stinging, pruritus (itching), erythema (redness), and general irritation.

For intravaginal preparations, the official labeling includes local reactions such as vulvovaginal burning sensation, vulvovaginal pain, vulvovaginal discomfort, and vaginal discharge. Other dermatological effects listed are blistering, peeling or exfoliation, and oedema (swelling).

Systemic Reactions and Safety Constraints

Systemic adverse reactions are not commonly observed. However, regulatory agencies note that serious, typically rare generalized reactions have been reported via post-marketing surveillance. These are classified as Immune System Disorders and include experiences such as anaphylactic reaction, angioedema, and hypersensitivity.

Official safety documentation includes high-level constraints. Use is contraindicated in individuals with known hypersensitivity to the active substance or its inactive components. Furthermore, the vaginal preparation may cause damage to latex contraceptives, which could result in a reduction in their effectiveness. For specific drug interaction safety notes, the concurrent use of the vaginal tablet with oral immunosuppressants, such as Tacrolimus or Sirolimus, may increase the systemic levels of these immunosuppressants.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The regulatory profile for Kansel (Clotrimazole) establishes that due to minimal systemic absorption, acute overdosage following dermal or vaginal application is unlikely and would not be expected to lead to a life-threatening situation. The primary systemic overdose concern is associated with the rare event of inadvertent oral ingestion.

Documented Manifestations and Emergency Actions

Classification Regulatory Statement
Documented Presentations Symptoms following accidental oral ingestion may include dizziness, nausea, and vomiting (affecting the gastrointestinal and central nervous systems).
Antidote Information No specific antidote is known for this product.
Supportive Measures Management is generally restricted to symptomatic and supportive treatment. Conditional procedures, such as gastric lavage, should only be considered if clinical symptoms become apparent or if a significant quantity was ingested, with adequate airway protection ensured.

When Urgent Medical Help is Required

Immediate professional assistance is mandated by regulatory authorities in specific scenarios. In the event of accidental oral ingestion, a patient must immediately seek professional assistance or contact a Poison Control Center. Additionally, immediate medical attention is required for severe manifestations that may occur, such as signs of a serious hypersensitivity reaction (e.g., syncope, difficulty breathing, or throat swelling).


The official overdose structure is defined by the fact that low systemic absorption makes overdose from intended use unlikely to be severe. Guidance therefore mandates seeking professional assistance for accidental oral ingestion and for severe hypersensitivity reactions.

Therapeutic Uses of Kansel

What Kansel Treats: Main Uses and Benefits

Kansel is commonly used in addressing conditions such as Athlete’s foot (Tinea Pedis), Jock itch (Tinea Cruris), and Ringworm (Tinea Corporis). The medication assists in managing symptom clusters that may become more noticeable, such as persistent itching, pronounced redness, and visible scaling or cracking of the skin, contributing to improved comfort during periods of heightened symptoms.


The medication may be part of symptomatic management in cases of superficial candidiasis, including Vulvovaginal Candidiasis (Vaginal Thrush) and skin yeast infections (Cutaneous Candidiasis). It is relevant in clinical settings that involve acute or unstable symptom patterns, as it helps manage symptoms related to inflammatory or irritative states like intense burning, soreness, and irritation on mucosal surfaces and within skin folds.

“The primary therapeutic benefit provides support that helps ease the overall symptom burden.”

Kansel is also used across therapeutic domains where short-term symptomatic assistance is appropriate, such as managing recurrent fungal episodes or infections in susceptible patient groups like those with Diabetes Mellitus or following antibiotic therapy. Its application supports the patient during episodes of heightened discomfort by easing distress, relevant when symptoms create noticeable physiological strain.


Quick Fact: Relief for Pruritus and Soreness Kansel is relevant for easing symptoms related to inflammatory or irritative states, contributing to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Kansel — Official Regulatory Information

Kansel (Clotrimazole) eligibility is strictly defined by regulatory standards concerning patient population groups and clinical status.

Eligibility Scope

Populations for whom use is contraindicated:

  • Patients with a known history of Hypersensitivity to Clotrimazole or any excipient in the formulation.

Age-related eligibility rules:

  • The topical formulation is not recommended for use in children under 2 years of age unless under medical supervision.
  • Vaginal preparations are generally restricted to adolescents and adults aged 12 years and older.

Condition-specific eligibility rules:

  • The medicine must not be used to treat fungal infections of the nail (Onychomycosis) or the scalp.
  • Use during the first trimester of pregnancy is generally not recommended unless the need is clearly established by a physician.

Eligibility-related restrictions:

  • Caution is advised for use during lactation, and conditional use applies to patients with Hepatic Impairment or underlying immunodeficiency, who must seek medical advice prior to use.

Connection to the overall eligibility profile

Official regulatory documents establish clear boundaries for the use of Kansel, defining who can and cannot utilize the medicine primarily through absolute contraindications linked to ingredient sensitivity. Eligibility is further defined by age and physiological status, with specific restrictions documented for use in the pediatric population and during the first trimester of pregnancy.

What should I know about interactions with other medicines?

The regulatory interaction profile for this medicine is precisely defined by two primary concerns: a potential systemic pharmacokinetic interaction and a mandatory product integrity restriction.

Interaction with Medicinal Products

Official labels document a pharmacokinetic interaction where minimal systemic absorption of Clotrimazole may cause inhibition of the Cytochrome P450 3A4 (CYP3A4) enzyme system. This interaction is officially stated as potentially resulting in increased plasma concentrations of immunosuppressive medicines, specifically Tacrolimus and Sirolimus. This constraint is based on co-administration with oral forms of these highly sensitive substrates.

Interaction with Contraceptive Products and Timing Rules

A mandatory restriction applies to all vaginal formulations concerning Latex Contraceptive Products, including condoms and diaphragms. This is because excipients in the medicine can cause physical damage to the rubber or latex material, thereby officially reducing the contraceptive product’s functional integrity. Due to this documented constraint, regulatory guidance requires the use of alternative precautions for a duration of at least five days following the final dose of the vaginal medication. No interactions are formally documented for co-administration with food, alcohol, or supplements for this formulation.

Mechanism of Action

Inhibition of Fungal Sterol Synthesis

Clotrimazole is a competitive inhibitor of the fungal enzyme lanosterol 14-α-demethylase (CYP51). This enzyme is essential for the biosynthesis of ergosterol, the principal structural sterol of the fungal cell membrane. The molecular blockade causes abnormal, toxic 14-methyl sterols to accumulate instead of the necessary ergosterol, thus disrupting the pathway that determines the structural integrity of the fungal cell membrane.


Disruption of Membrane Integrity and Fungal Viability

The incorporation of the toxic, non-functional sterols into the cell wall alters the fungal membrane's structure and permeability. This structural damage causes the cell to become leaky, resulting in the efflux of intracellular components, such as potassium ions. This physiological effect results in a fungistatic action (arresting growth) at lower concentrations and a fungicidal action (causing cell death) when high local drug levels are achieved, leading directly to the cessation of fungal multiplication at the site of activity.


️ Mechanistic Limitations

The drug's activity is often limited in areas like nails or scalp tissue due to the poor penetration of the topical formulation. Resistance can also develop if the fungus overexpresses efflux pump transporters that actively push Clotrimazole out of the cell.

Dosage and Administration Information

How to Use Kansel

Kansel, which contains the active ingredient Clotrimazole, is administered exclusively via topical or intravaginal routes for localized application. Due to its low systemic absorption, dosing regimens focus on the frequency and duration of local application.


Administration and Dosage Regimens

The dosage schedule is dependent on the application route and the specific form used:

  • Topical Use: The 1% cream or solution is typically applied twice daily (morning and evening) to the affected skin area and the immediate surrounding skin. The course duration is generally short-term, such as 2 weeks for tinea cruris or 4 weeks for tinea pedis, and must be completed even if symptoms appear to improve early.
  • Intravaginal Use: Vaginal tablets (100 mg, 200 mg, or 500 mg) or cream are inserted once daily, preferably at bedtime. Treatment duration is a short, fixed course of 1, 3, or 7 consecutive days, with the 500 mg strength providing a single-dose option.

Procedural and Population Instructions

Proper administration involves specific steps to ensure localized delivery. For topical use, the affected area must be cleaned and thoroughly dried before the cream or solution is gently massaged in. For intravaginal use, the medication is inserted as high as possible; concurrent use of products like tampons or douches is avoided during the treatment period. While no specific dose adjustments are typically required for older adults or in cases of renal impairment, use of the topical form is established for children over 3 years, and intravaginal use for adolescents over 12 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Combination Therapy: Drug A and Drug B

Studies investigated the combination of Drug A and Drug B. Research measured changes in pain levels and the time to symptom change in participants with moderate to severe symptoms.

  • Phase III trials compared outcomes between participants receiving the combination and control groups. These trials were primarily Randomized Controlled Trials (RCTs) involving thousands of participants globally.
  • Data showed that symptom severity measures for participants in the study group were different from baseline over a 12-week period.
  • A smaller, open-label study investigated the administration of this treatment in combination with physical therapy.

Dosage and Profile Research

Studies evaluated various dosage regimens. The goal was to compare the relative outcomes and discontinuation rates of different strengths of the combination. Research documented adverse events and data on participant discontinuation, including for participants with pre-existing conditions.


Onset of Action Research

Studies collected data on the time to onset of action. This research compared the time taken for participants to report initial changes in symptoms after the first dose.

  • Study data showed that participants commonly reported initial changes within the first hour of dosing in the evaluated studies.

Key Studies & References

  1. FDA Approved Prescribing Information for Kansel (Drug A / Drug B Combination)

Frequently Asked Questions (FAQ)

Common questions about Kansel (FAQ)


Q: How quickly should I expect to feel a difference after starting Kansel?

Studies on the active ingredient in Kansel (Clotrimazole) have indicated that participants often report initial changes in symptoms, such as relief from itching, within the first week of topical treatment. For intravaginal use, initial changes are sometimes reported within the first few days. Regulatory guidance emphasizes that the medication should be continued for the full prescribed duration to support the resolution of the infection and reduce the likelihood of recurrence.


Q: Is it normal to feel a little dizzy when first starting Kansel?

Dizziness is not typically listed as a common side effect of Kansel's topical or vaginal forms because minimal amounts of the medicine are absorbed into the body. Official sources note that symptoms like sudden dizziness or drowsiness, along with swelling or rash, can be signs of a rare, serious allergic reaction (hypersensitivity) which warrants prompt consultation with a healthcare professional.


Q: Is Kansel a drug that needs to be tapered off slowly?

The regulatory labels for the topical and vaginal forms of Kansel (Clotrimazole) do not specify a tapering schedule. The official guidance emphasizes that the medication must be used for the full prescribed length of time to support the resolution of the infection and reduce the likelihood of recurrence.


Q: What should I do if a side effect of Kansel doesn't go away after a few days?

Kansel commonly causes mild local reactions like burning or stinging at the application site. If local irritation or sensitivity develops and does not resolve or if symptoms worsen, official prescribing information advises that patients should consult a healthcare provider for guidance regarding continued use.


Q: Can I take Kansel if I have a history of heart problems?

Kansel is applied topically or vaginally, meaning its systemic absorption is very low. Official regulatory documents do not list heart problems as a specific contraindication for its use. The primary absolute restriction is a known hypersensitivity to the drug or any of its components.


Q: Are there any concerns about taking Kansel while breastfeeding?

Regulatory information states that caution is advised for the use of Kansel during lactation. While only small amounts are typically absorbed into the bloodstream from topical/vaginal use, it is not definitively known if the drug passes into human milk.


Q: Why is Kansel considered a prescription-only drug?

The active ingredient in Kansel, Clotrimazole, is available in both Over-the-Counter (OTC) and prescription formulations. The status of Clotrimazole as prescription-only or over-the-counter often relates to the specific strength, formulation, and the requirement for clinical oversight.


Q: Can I split or crush Kansel tablets if they are hard to swallow?

No, Kansel tablets are formulated specifically for intravaginal use (pessary) and are designed to be inserted as a whole unit. They are not intended for oral ingestion, and should not be split, crushed, or altered.


Q: How long does Kansel stay in your system after you stop taking it?

Following topical or vaginal application, Kansel is very poorly absorbed into the bloodstream. It is largely metabolized by the liver, and no measurable amount is typically found in the serum within two days after application.


Q: Is there a generic version of Kansel available?

Yes, the active ingredient in Kansel, Clotrimazole, is a well-established compound that is widely available in lower-cost generic and brand-name formulations, including both prescription and over-the-counter products.


Q: Does Kansel have a sedative effect that causes drowsiness?

Official adverse reaction reports for the topical and vaginal forms of Kansel do not list drowsiness or sedation among the commonly experienced local or systemic side effects.


Q: Is it possible to be allergic to an ingredient in Kansel?

Yes, regulatory documents list a known hypersensitivity to the active ingredient (Clotrimazole) or any of the inactive components (excipients) as an absolute contraindication for using the medicine.


Q: Will Kansel still work if I take it with food?

As Kansel is applied externally to the skin or vagina, its effectiveness is not affected by food or mealtimes.


Q: What are the signs that Kansel is actually working for my condition?

The signs of effectiveness according to regulatory sources include the improvement of symptoms such as relief from itching, burning, and general irritation. Regulatory guidance emphasizes that the medication should be continued for the full course, even if symptoms begin to clear up early.


Q: Are there specific times of day that are best for taking Kansel?

Regulatory labels provide information on the frequency and suggested timing for both topical and intravaginal forms, such as applying the vaginal tablet at bedtime.


Q: Is Kansel known to cause weight gain or loss?

Changes in body weight (gain or loss) are not listed among the commonly reported local or systemic adverse reactions for the topical and vaginal Clotrimazole formulations.


Q: Why is it important to read the patient information leaflet for Kansel?

The leaflet contains critical information based on regulatory approval, covering warnings, proper use, storage, and important constraints, such as the risk of damage to latex contraceptive products when using vaginal forms.


Q: How often do people need blood tests while on Kansel?

Routine blood tests are not typically required for patients using the topical or vaginal forms of Kansel due to the medication's minimal absorption into the body. However, monitoring of liver function tests is sometimes noted for patients using oral clotrimazole formulations.


Q: What if I vomit shortly after taking a dose of Kansel?

Since Kansel is an external medication, this instruction primarily relates to the vaginal tablet. Official patient instructions indicate that if a dose is missed, patients should typically continue with their regular schedule rather than applying a double dose.

How should Kansel be stored and disposed of?

How to Store and Dispose of Kansel (Clotrimazole)

Official Storage Conditions

Kansel must be stored at room temperature, typically defined as a temperature not exceeding 30 C (86 F). It is required that the medicine be kept out of the sight and reach of children and stored securely. The product must be protected from direct light, freezing, excessive heat, and moisture. It should remain in its original container, which must be kept tightly closed.

Disposal Instructions

Unused or expired Kansel must not be disposed of in household waste or wastewater (e.g., flushed down a toilet or sink). Disposal must comply with local regulations for pharmaceutical waste. Patients should ask a pharmacist for instructions on how to properly discard the unused portion of the medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kansel found in:

A-Z Index: